Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of 92.50 million. The enterprise value is 124.62 million.

Market Cap	92.50M
Enterprise Value	124.62M

Important Dates

The next estimated earnings date is Friday, July 18, 2025.

Earnings Date	Jul 18, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	91.43M
Shares Outstanding	n/a
Shares Change (YoY)	+1.66%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	44.71M

Valuation Ratios

The trailing PE ratio is 9.96.

PE Ratio	9.96
Forward PE	n/a
PS Ratio	1.42
PB Ratio	1.42
P/TBV Ratio	1.42
P/FCF Ratio	29.44
P/OCF Ratio	12.36
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.53, with an EV/FCF ratio of 39.66.

EV / Earnings	13.42
EV / Sales	1.81
EV / EBITDA	7.53
EV / EBIT	10.56
EV / FCF	39.66

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.52.

Current Ratio	2.35
Quick Ratio	0.64
Debt / Equity	0.52
Debt / EBITDA	2.16
Debt / FCF	10.78
Interest Coverage	3.55

Financial Efficiency

Return on equity (ROE) is 15.44% and return on invested capital (ROIC) is 7.41%.

Return on Equity (ROE)	15.44%
Return on Assets (ROA)	6.55%
Return on Invested Capital (ROIC)	7.41%
Return on Capital Employed (ROCE)	12.45%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.61
Inventory Turnover	1.33

Taxes

In the past 12 months, Cannara Biotech has paid 130,544 in taxes.

Income Tax	130,544
Effective Tax Rate	1.39%

Stock Price Statistics

The stock price has increased by +79.96% in the last 52 weeks. The beta is 0.23, so Cannara Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+79.96%
50-Day Moving Average	0.93
200-Day Moving Average	0.70
Relative Strength Index (RSI)	63.79
Average Volume (20 Days)	10,313

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of 65.19 million and earned 9.28 million in profits. Earnings per share was 0.10.

Revenue	65.19M
Gross Profit	27.29M
Operating Income	11.16M
Pretax Income	9.41M
Net Income	9.28M
EBITDA	15.45M
EBIT	11.16M
Earnings Per Share (EPS)	0.10

Full Income Statement

Balance Sheet

The company has 3.50 million in cash and 33.86 million in debt, giving a net cash position of -30.36 million.

Cash & Cash Equivalents	3.50M
Total Debt	33.86M
Net Cash	-30.36M
Net Cash Per Share	n/a
Equity (Book Value)	65.27M
Book Value Per Share	0.71
Working Capital	29.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.48 million and capital expenditures -4.34 million, giving a free cash flow of 3.14 million.

Operating Cash Flow	7.48M
Capital Expenditures	-4.34M
Free Cash Flow	3.14M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 41.86%, with operating and profit margins of 17.12% and 14.24%.

Gross Margin	41.86%
Operating Margin	17.12%
Pretax Margin	14.44%
Profit Margin	14.24%
EBITDA Margin	23.70%
EBIT Margin	17.12%
FCF Margin	4.82%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.66%
Shareholder Yield	n/a
Earnings Yield	10.04%
FCF Yield	3.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.8
Piotroski F-Score	5